Zerr, Inga

[["dc.bibliographiccitation.firstpage","8680"],["dc.bibliographiccitation.issue","22"],["dc.bibliographiccitation.journal","International Journal of Molecular Sciences"],["dc.bibliographiccitation.volume","21"],["dc.contributor.affiliation","Andrés-Benito, Pol; \t\t \r\n\t\t Department of Pathology and Experimental Therapeutics, University of Barcelona, Feixa Llarga s/n, 08907 L’Hospitalet de Llobregat, Barcelona, Spain, pol.andres.benito@gmail.com\t\t \r\n\t\t Biomedical Network Research Center on Neurodegenerative Diseases (CIBERNED), Institute Carlos III, Feixa Llarga s/n, 08907 L’Hospitalet de Llobregat, Barcelona, Spain, pol.andres.benito@gmail.com\t\t \r\n\t\t Bellvitge Biomedical Research Institute (IDIBELL), 08907 L’Hospitalet de Llobregat, Barcelona, Spain, pol.andres.benito@gmail.com\t\t \r\n\t\t Institute of Neurosciences, University of Barcelona, 08907 L’Hospitalet de Llobregat, Barcelona, Spain, pol.andres.benito@gmail.com\t\t \r\n\t\t International Initiative for Treatment and Research Initiative to Cure ALS (TRICALS), Bellvitge University Hospital, 08907 Hospitalet de Llobregat, Spain, pol.andres.benito@gmail.com"],["dc.contributor.affiliation","Povedano, Mònica; \t\t \r\n\t\t International Initiative for Treatment and Research Initiative to Cure ALS (TRICALS), Bellvitge University Hospital, 08907 Hospitalet de Llobregat, Spain, mpovedano@bellvitgehospital.cat\t\t \r\n\t\t Functional Unit of Amyotrophic Lateral Sclerosis (UFELA), Service of Neurology, Bellvitge University Hospital, 08907 L’Hospitalet de Llobregat, Barcelona, Spain, mpovedano@bellvitgehospital.cat"],["dc.contributor.affiliation","Domínguez, Raúl; \t\t \r\n\t\t International Initiative for Treatment and Research Initiative to Cure ALS (TRICALS), Bellvitge University Hospital, 08907 Hospitalet de Llobregat, Spain, rdominguez@bellvitgehospital.cat"],["dc.contributor.affiliation","Marco, Carla; \t\t \r\n\t\t International Initiative for Treatment and Research Initiative to Cure ALS (TRICALS), Bellvitge University Hospital, 08907 Hospitalet de Llobregat, Spain, carlamarcocazcarra@gmail.com"],["dc.contributor.affiliation","Colomina, Maria J.; \t\t \r\n\t\t Anesthesia and Critical Care Department, Bellvitge University Hospital-University of Barcelona, 08907 L’Hospitalet de Llobregat, Barcelona, Spain, Mjcolomina@gmail.com"],["dc.contributor.affiliation","López-Pérez, Óscar; \t\t \r\n\t\t Biomedical Network Research Center on Neurodegenerative Diseases (CIBERNED), Institute Carlos III, Feixa Llarga s/n, 08907 L’Hospitalet de Llobregat, Barcelona, Spain, oscarlzpz@gmail.com"],["dc.contributor.affiliation","Santana, Isabel; \t\t \r\n\t\t Neurology Department, CHUC—Centro Hospitalar e Universitário de Coimbra, CNC—Center for Neuroscience and Cell Biology; and Faculty of Medicine, University of Coimbra, 3000-456 Coimbra, Portugal, isabeljsantana@gmail.com"],["dc.contributor.affiliation","Baldeiras, Inês; \t\t \r\n\t\t Neurology Department, CHUC—Centro Hospitalar e Universitário de Coimbra, CNC—Center for Neuroscience and Cell Biology; and Faculty of Medicine, University of Coimbra, 3000-456 Coimbra, Portugal, ines.baldeiras@sapo.pt"],["dc.contributor.affiliation","Martínez-Yelámos, Sergio; \t\t \r\n\t\t Multiple Sclerosis Unit, Service of Neurology, Bellvitge University Hospital, 08907 L’Hospitalet de Llobregat, Barcelona, Spain, smartinezy@bellvitgehospital.cat"],["dc.contributor.affiliation","Zerr, Inga; \t\t \r\n\t\t Department of Neurology, University Medical Center Göttingen, 37075 Göttingen, Germany, ingazerr@med.uni-goettingen.de\t\t \r\n\t\t German Center for Neurodegenerative Diseases (DZNE), 37075 Göttingen, Germany, ingazerr@med.uni-goettingen.de"],["dc.contributor.affiliation","Llorens, Franc; \t\t \r\n\t\t Department of Pathology and Experimental Therapeutics, University of Barcelona, Feixa Llarga s/n, 08907 L’Hospitalet de Llobregat, Barcelona, Spain, franc.llorens@gmail.com\t\t \r\n\t\t Biomedical Network Research Center on Neurodegenerative Diseases (CIBERNED), Institute Carlos III, Feixa Llarga s/n, 08907 L’Hospitalet de Llobregat, Barcelona, Spain, franc.llorens@gmail.com\t\t \r\n\t\t Bellvitge Biomedical Research Institute (IDIBELL), 08907 L’Hospitalet de Llobregat, Barcelona, Spain, franc.llorens@gmail.com\t\t \r\n\t\t Institute of Neurosciences, University of Barcelona, 08907 L’Hospitalet de Llobregat, Barcelona, Spain, franc.llorens@gmail.com"],["dc.contributor.affiliation","Fernández-Irigoyen, Joaquín; \t\t \r\n\t\t IDISNA, Navarra Institute for Health Research, 31008 Pamplona, Spain, joaquin.fernandez.irigoyen@navarra.es\t\t \r\n\t\t Clinical Neuroproteomics Unit, Proteomics Platform, Proteored-ISCIII, Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), 31008 Pamplona, Spain, joaquin.fernandez.irigoyen@navarra.es"],["dc.contributor.affiliation","Santamaría, Enrique; \t\t \r\n\t\t IDISNA, Navarra Institute for Health Research, 31008 Pamplona, Spain, enrique.santamaria.martinez@navarra.es\t\t \r\n\t\t Clinical Neuroproteomics Unit, Proteomics Platform, Proteored-ISCIII, Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), 31008 Pamplona, Spain, enrique.santamaria.martinez@navarra.es"],["dc.contributor.affiliation","Ferrer, Isidro; \t\t \r\n\t\t Department of Pathology and Experimental Therapeutics, University of Barcelona, Feixa Llarga s/n, 08907 L’Hospitalet de Llobregat, Barcelona, Spain, 8082ifa@gmail.com\t\t \r\n\t\t Biomedical Network Research Center on Neurodegenerative Diseases (CIBERNED), Institute Carlos III, Feixa Llarga s/n, 08907 L’Hospitalet de Llobregat, Barcelona, Spain, 8082ifa@gmail.com\t\t \r\n\t\t Bellvitge Biomedical Research Institute (IDIBELL), 08907 L’Hospitalet de Llobregat, Barcelona, Spain, 8082ifa@gmail.com\t\t \r\n\t\t Institute of Neurosciences, University of Barcelona, 08907 L’Hospitalet de Llobregat, Barcelona, Spain, 8082ifa@gmail.com\t\t \r\n\t\t International Initiative for Treatment and Research Initiative to Cure ALS (TRICALS), Bellvitge University Hospital, 08907 Hospitalet de Llobregat, Spain, 8082ifa@gmail.com\t\t \r\n\t\t Neuropathology, Pathologic Anatomy Service, Bellvitge University Hospital, 08907 L’Hospitalet de Llobregat, Barcelona, Spain, 8082ifa@gmail.com"],["dc.contributor.author","Andrés-Benito, Pol"],["dc.contributor.author","Povedano, Mònica"],["dc.contributor.author","Domínguez, Raúl"],["dc.contributor.author","Marco, Carla"],["dc.contributor.author","Colomina, Maria J."],["dc.contributor.author","López-Pérez, Óscar"],["dc.contributor.author","Santana, Isabel"],["dc.contributor.author","Baldeiras, Inês"],["dc.contributor.author","Martínez-Yelámos, Sergio"],["dc.contributor.author","Zerr, Inga"],["dc.contributor.author","Llorens, Franc"],["dc.contributor.author","Fernández-Irigoyen, Joaquín"],["dc.contributor.author","Santamaría, Enrique"],["dc.contributor.author","Ferrer, Isidro"],["dc.date.accessioned","2021-04-14T08:31:05Z"],["dc.date.available","2021-04-14T08:31:05Z"],["dc.date.issued","2020"],["dc.date.updated","2022-09-05T14:19:42Z"],["dc.identifier.doi","10.3390/ijms21228680"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83483"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1422-0067"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Increased C-X-C Motif Chemokine Ligand 12 Levels in Cerebrospinal Fluid as a Candidate Biomarker in Sporadic Amyotrophic Lateral Sclerosis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","800"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Biomolecules"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Zerr, Inga"],["dc.contributor.author","Villar-Piqué, Anna"],["dc.contributor.author","Schmitz, Vanda Edit"],["dc.contributor.author","Poleggi, Anna"],["dc.contributor.author","Pocchiari, Maurizio"],["dc.contributor.author","Sánchez-Valle, Raquel"],["dc.contributor.author","Calero, Miguel"],["dc.contributor.author","Calero, Olga"],["dc.contributor.author","Baldeiras, Inês"],["dc.contributor.author","Santana, Isabel"],["dc.contributor.author","Kovacs, Gabor G."],["dc.contributor.author","Llorens, Franc"],["dc.contributor.author","Schmitz, Matthias"],["dc.date.accessioned","2020-12-10T18:46:57Z"],["dc.date.available","2020-12-10T18:46:57Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.3390/biom9120800"],["dc.identifier.eissn","2218-273X"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16939"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78595"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","MDPI"],["dc.relation.eissn","2218-273X"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Evaluation of Human Cerebrospinal Fluid Malate Dehydrogenase 1 as a Marker in Genetic Prion Disease Patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Nature Communications"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Llorens, Franc"],["dc.contributor.author","Hermann, Peter"],["dc.contributor.author","Villar-Piqué, Anna"],["dc.contributor.author","Diaz-Lucena, Daniela"],["dc.contributor.author","Nägga, Katarina"],["dc.contributor.author","Hansson, Oskar"],["dc.contributor.author","Santana, Isabel"],["dc.contributor.author","Schmitz, Matthias"],["dc.contributor.author","Schmidt, Christian"],["dc.contributor.author","Varges, Daniela"],["dc.contributor.author","Goebel, Stefan"],["dc.contributor.author","Dumurgier, Julien"],["dc.contributor.author","Zetterberg, Henrik"],["dc.contributor.author","Blennow, Kaj"],["dc.contributor.author","Paquet, Claire"],["dc.contributor.author","Baldeiras, Inês"],["dc.contributor.author","Ferrer, Isidro"],["dc.contributor.author","Zerr, Inga"],["dc.date.accessioned","2021-04-14T08:27:37Z"],["dc.date.available","2021-04-14T08:27:37Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1038/s41467-020-14373-2"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17201"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82349"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","2041-1723"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","9"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Alzheimer's Research & Therapy"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Hermann, Peter"],["dc.contributor.author","Villar-Piqué, Anna"],["dc.contributor.author","Schmitz, Matthias"],["dc.contributor.author","Schmidt, Christian"],["dc.contributor.author","Varges, Daniela"],["dc.contributor.author","Goebel, Stefan"],["dc.contributor.author","Bunck, Timothy"],["dc.contributor.author","Lindemann, Hanna"],["dc.contributor.author","Bogner, Carla"],["dc.contributor.author","Santana, Isabel"],["dc.contributor.author","Baldeiras, Inês"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Zerr, Inga"],["dc.contributor.author","Llorens, Franc"],["dc.date.accessioned","2022-02-01T10:31:33Z"],["dc.date.accessioned","2022-08-18T12:39:24Z"],["dc.date.available","2022-02-01T10:31:33Z"],["dc.date.available","2022-08-18T12:39:24Z"],["dc.date.issued","2022-01-13"],["dc.date.updated","2022-07-29T12:17:51Z"],["dc.description.abstract","Background Lipocalin-2 is a glycoprotein that is involved in various physiological and pathophysiological processes. In the brain, it is expressed in response to vascular and other brain injury, as well as in Alzheimer’s disease in reactive microglia and astrocytes. Plasma Lipocalin-2 has been proposed as a biomarker for Alzheimer’s disease but available data is scarce and inconsistent. Thus, we evaluated plasma Lipocalin-2 in the context of Alzheimer’s disease, differential diagnoses, other biomarkers, and clinical data. Methods For this two-center case-control study, we analyzed Lipocalin-2 concentrations in plasma samples from a cohort of n  = 407 individuals. The diagnostic groups comprised Alzheimer’s disease ( n  = 74), vascular dementia ( n  = 28), other important differential diagnoses ( n  = 221), and healthy controls ( n  = 84). Main results were validated in an independent cohort with patients with Alzheimer’s disease ( n  = 19), mild cognitive impairment ( n  = 27), and healthy individuals ( n  = 28). Results Plasma Lipocalin-2 was significantly lower in Alzheimer’s disease compared to healthy controls ( p  < 0.001) and all other groups ( p  < 0.01) except for mixed dementia (vascular and Alzheimer’s pathologic changes). Areas under the curve from receiver operation characteristics for the discrimination of Alzheimer’s disease and healthy controls were 0.783 (95%CI: 0.712–0.855) in the study cohort and 0.766 (95%CI: 0.627–0.905) in the validation cohort. The area under the curve for Alzheimer’s disease versus vascular dementia was 0.778 (95%CI: 0.667–0.890) in the study cohort. In Alzheimer’s disease patients, plasma Lipocalin2 did not show significant correlation with cerebrospinal fluid biomarkers of neurodegeneration and AD-related pathology (total-tau, phosphorylated tau protein, and beta-amyloid 1-42), cognitive status (Mini Mental Status Examination scores), APOE genotype, or presence of white matter hyperintensities. Interestingly, Lipocalin 2 was lower in patients with rapid disease course compared to patients with non-rapidly progressive Alzheimer’s disease ( p  = 0.013). Conclusions Plasma Lipocalin-2 has potential as a diagnostic biomarker for Alzheimer’s disease and seems to be independent from currently employed biomarkers."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.citation","Alzheimer's Research & Therapy. 2022 Jan 13;14(1):9"],["dc.identifier.doi","10.1186/s13195-021-00955-9"],["dc.identifier.pii","955"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/98886"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112969"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-517"],["dc.publisher","BioMed Central"],["dc.relation.eissn","1758-9193"],["dc.rights","CC BY 4.0"],["dc.rights.holder","The Author(s)"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject","Dementia"],["dc.subject","Alzheimer’s disease"],["dc.subject","Biomarker"],["dc.subject","Plasma"],["dc.subject","Lipocalin 2"],["dc.subject","Neutrophil gelatinase-associated Lipocalin"],["dc.title","Plasma Lipocalin 2 in Alzheimer’s disease: potential utility in the differential diagnosis and relationship with other biomarkers"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]